A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancerstage C hepatocellular carcinoma with poor liver function
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS. Results: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008). Conclusions: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Abstract
Background/Aims: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT). Methods: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS. Results: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008). Conclusions: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
참고문헌 (26)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Llovet JM, "Prognosis of hepatocellular carcinoma: the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
- Llovet JM, "Hepatocellular carcinoma", Lancet, 362, pp.1907~1917 (2003)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Woo HY, "New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis", Clin Mol Hepatol, 21, pp.115~121 (2015)
- DA Fonseca LG, "Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma", Mol Clin Oncol, 3, pp.793~796 (2015)
- Lee SH, "Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions", BMC Cancer, 15, pp.236~ (2015)
- Kim JE, "Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function", Cancer Chemother Pharmacol, 68, pp.1285~1290 (2011)
- Hanahan D, "Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice", J Clin Invest, 105, pp.1045~1047 (2000)
- Pasquier E, "Metronomic chemotherapy: new rationale for new directions", Nat Rev Clin Oncol, 7, pp.455~465 (2010)
- 우현영, "Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis", Clinical and Molecular Hepatology, 18(1), pp.32~40 (2012), 대한간학회
- Park ST, "Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis", Cancer Chemother Pharmacol, 65, pp.1029~1037 (2010)
- Torimura T, "Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma", Transl Oncol, 6, pp.511~519 (2013)
- Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 65, pp.373~382 (2010)
- Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Song DS, "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", J Gastroenterol, 50, pp.445~454 (2015)
- Treiber G, "Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer", J Cancer Res Clin Oncol, 135, pp.271~281 (2009)
- Shao YY, "Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma", Oncology, 82, pp.59~66 (2012)
- Hsu CH, "Phase II study of combining sorafenib with metronomic tegafur", uracil for advanced hepatocellular carcinoma, 2010, pp.53, 126~131
- Brandi G, "Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study", Oncologist, 18, pp.1256~1257 (2013)
- Sohn W, "Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread:treatment outcome and prognostic factors", J Hepatol, 62, pp.1112~1121 (2015)
- 김희언, "A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma", Clinical and Molecular Hepatology, 16(4), pp.355~361 (2010), 대한간학회
- Jang JW, "Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma", Cancer Chemother Pharmacol, 54, pp.415~420 (2004)
- Vu NB, "Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties", Cytotechnology, 65, pp.491~503 (2013)
- Yang H, "Comparative study between metronomic chemotherapy and transarterial chemoembolization in patients with Child-Pugh class B advanced hepatocellular carcinoma", J Liver Cancer, 15, pp.92~99 (2015)